TB R&D Weekly Update: Results from Preventative Therapy Trial in SA Miners

At the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, results on the Thibela TB preventative therapy trial in South Africa gold miners was presented with mixed outcomes. On one hand, the number of cases in miners in the experimental group who screened negative for TB received daily isoniazid preventative therapy for 9 months was significantly less than miners who did not receive preventative therapy, but the overall incidence was not significantly different between mines in the experimental group and mines in the control group. All miners who screened positive for TB were treated with standard therapy. Due to the nature of their work, miners have a much higher risk of developing active TB then the general population. The research was conducted by the Aurum Institute (Johannesburg, South Africa) and the London School of Hygiene and Tropical Medicine (United Kingdom)

Additional Coverage:

Study deflates hopes for daily TB pill

Five-cent-a-day preventive treatment can reduce TB cases among miners by 63%

TB control in mines disappoints

South Africa sets goal of testing all miners for tuberculosis, getting sufferers treated

Additional TB R&D News:

EpiStem Holdings Plc : Epistem signs tuberculosis channel partner agreement

Combating Childhood Tuberculosis

World Tuberculosis Day around the Bend

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...